Voyager Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Voyager Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2016 to Q3 2024.
  • Voyager Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 35.4 %, a 49.3% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 35.4 -34.4 -49.3% Sep 30, 2024
Q2 2024 42.5 -36.6 -46.2% Jun 30, 2024
Q1 2024 50.3 -58.2 -53.7% Mar 31, 2024
Q4 2023 56.6 -118 -67.6% Dec 31, 2023
Q3 2023 69.8 -84 -54.6% Sep 30, 2023
Q2 2023 79.1 -69.4 -46.7% Jun 30, 2023
Q1 2023 108 -11.5 -9.62% Mar 31, 2023
Q4 2022 175 +82.4 +89.3% Dec 31, 2022
Q3 2022 154 +71.1 +85.9% Sep 30, 2022
Q2 2022 149 +76.2 +105% Jun 30, 2022
Q1 2022 120 +20.1 +20.1% Mar 31, 2022
Q4 2021 92.2 -49.1 -34.7% Dec 31, 2021
Q3 2021 82.8 -112 -57.5% Sep 30, 2021
Q2 2021 72.4 -198 -73.3% Jun 30, 2021
Q1 2021 99.9 -156 -60.9% Mar 31, 2021
Q4 2020 141 -117 -45.4% Dec 31, 2020
Q3 2020 195 -67.5 -25.7% Sep 30, 2020
Q2 2020 271 +16.3 +6.4% Jun 30, 2020
Q1 2020 255 +16 +6.68% Mar 31, 2020
Q4 2019 259 +76.9 +42.3% Dec 31, 2019
Q3 2019 262 +143 +121% Sep 30, 2019
Q2 2019 255 +161 +171% Jun 30, 2019
Q1 2019 239 +169 +242% Mar 31, 2019
Q4 2018 182 +135 +284% Dec 31, 2018
Q3 2018 119 +71 +148% Sep 30, 2018
Q2 2018 94 +52.7 +127% Jun 30, 2018
Q1 2018 70 +32.2 +85.2% Mar 31, 2018
Q4 2017 47.3 +11.4 +31.8% Dec 31, 2017
Q3 2017 47.8 +12.8 +36.3% Sep 30, 2017
Q2 2017 41.3 -12.1 -22.6% Jun 30, 2017
Q1 2017 37.8 Mar 31, 2017
Q4 2016 35.9 Dec 31, 2016
Q3 2016 35.1 Sep 30, 2016
Q2 2016 53.4 Jun 30, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.